Agios Pharmaceuticals (AGIO) Prepaid Assets (2012 - 2026)
Agios Pharmaceuticals' (AGIO) quarterly Prepaid Assets came in at $45.7 million in Q2 2026, up 2.31% YoY from $44.7 million in Q2 2025, and down 1.85% on a QoQ basis from $46.6 million in Q1 2026.
Analysis
Agios Pharmaceuticals (AGIO) Prepaid Assets (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals (AGIO) has 15 years of Prepaid Assets data on file, last reported at $45.7 million in Q2 2026.
- Quarterly Prepaid Assets rose 2.31% year-over-year to $45.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $45.7 million (up 2.31% YoY) and the FY2025 annual result came in at $44.1 million, up 9.87% from the prior year.
- Prepaid Assets slipped to $45.7 million in Q2 2026, from $46.6 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $46.6 million in Q1 2026 to a low of $34.5 million in Q2 2024.
- A 5-year average of $41.2 million and a median of $41.2 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets soared 121.55% — and 2023, when it declined 17.37%.
- Tracing AGIO's Prepaid Assets over 5 years: stood at $39.0 million in 2022, then slipped by 10.1% to $35.0 million in 2023, then advanced by 14.69% to $40.2 million in 2024, then rose by 9.87% to $44.1 million in 2025, then climbed by 3.61% to $45.7 million in 2026.
- The last three Prepaid Assets figures came in at $45.7 million (Q2 2026), $46.6 million (Q1 2026), and $44.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Agios Pharmaceuticals | 1.97 Bn | 1.97 Bn | 41.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 45.72 Mn |
| Mar 31, 2026 | 46.59 Mn |
| Dec 31, 2025 | 44.13 Mn |
| Sep 30, 2025 | 43.19 Mn |
| Jun 30, 2025 | 44.69 Mn |
| Mar 31, 2025 | 42.29 Mn |
| Dec 31, 2024 | 40.17 Mn |
| Sep 30, 2024 | 39.89 Mn |
| Jun 30, 2024 | 34.54 Mn |
| Mar 31, 2024 | 39.11 Mn |
| Dec 31, 2023 | 35.02 Mn |
| Sep 30, 2023 | 38.41 Mn |
| Jun 30, 2023 | 36.75 Mn |
| Mar 31, 2023 | 39.30 Mn |
| Dec 31, 2022 | 38.96 Mn |
| Sep 30, 2022 | 46.49 Mn |
| Jun 30, 2022 | 42.34 Mn |
| Mar 31, 2022 | 43.23 Mn |
| Dec 31, 2021 | 39.84 Mn |
| Sep 30, 2021 | 32.24 Mn |